PRJNA544233
A novel sulidac derivative protects retinal cells and the heart from oxidative damage
Oxidative damage is believed to play a significant in the etiology of many age related diseases. We have previously reported that sulindac, a known cyclooxygenase (COX) inhibitor and FDA approved anti-inflammatory drug, can initiate a pharmacological preconditioning response, similar to ischemic preconditioning (IPC). The current project aims to understand the mechanism of protection offered by MCI-100, a derivative of sulindac and sulindac against oxidative damage using RNA sequencing